Affinivax Inc: Overview

Affinivax Inc (Affinivax), a subsidiary of GSK plc, is a biopharmaceutical company that develops vaccines for infectious and immune-mediated diseases. It is investigating its lead vaccine candidate, AFX3772 to protect against streptococcus pneumoniae infections; and ASP1004 to prevent klebsiella pneumoniae and pseudomonas aeruginosa. The company is also developing vaccines targeting staphylococcus aureus and clostridium difficile bacterial infections, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and melanoma. Affinivax utilizes its proprietary multiple antigen presenting system (MAPS) platform to develop vaccines using high affinity biotin-rhizavidin binding interaction to exhibit the immunogenic epitopes of polysaccharide and protein antigens for strong immune protection. It works in collaboration with Astellas Pharma Inc, and the Bill & Melinda gates foundation to develop vaccines. Affinivax is headquartered in Cambridge, Massachusetts, the US.